Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron

Supportive Care in Cancer

Volumn 12, Issue 3, 2004, Pages 208-209

  Porzio, Giampiero ^a   Aielli, Federica ^a   Narducci, Filomena ^a   Cannita, Katia ^a   Piccolo, Domenico ^a   Marchetti, Paolo ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Granisetron; Pruritus

Indexed keywords

GRANISETRON; OPIATE;

ADULT; ADVANCED CANCER; ARTICLE; CASE REPORT; CHOLESTASIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG COST; FEMALE; HUMAN; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT;

AGED; FEMALE; GRANISETRON; HUMANS; INFUSIONS, INTRAVENOUS; NEOPLASMS; PRURITUS; SEROTONIN ANTAGONISTS;

EID: 1642264112     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-003-0581-2     Document Type: Article

References (8)

1. Albares MP, Betlloch I, Guijarro J, Vergara G, Pascual JC, Botella R (2003) Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. Br J Dermatol 148:376-377
2. Chung KC, Chin A, Gill MA (1995) Stability of granisetron hydrochloride in a disposable elastomeric infusion device. Am J Health Syst Pharm 52:1541-1543
3. Dimitrou V, Voyagis GS (1999) Opioid-induced pruritus: repeat vs single dose ondansetron administration in preventing pruritus after intrathecal morphine. Br J Anaest 83:822-826
4. Krajnik M, Zylicz Z (2001) Understanding pruritus in systemic disease. J Pain Symptom Manage 21:151-168
5. Lindstone V, Thorns A (2001) Pruritus in cancer patients. Cancer Treat Rev 27:305-312
6. Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ (2003) A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 148:314-317
7. Schworer H, Hartmann H, Ramadori G (1995) Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 61:33-37
8. Trissel LA, Gilbert DL, Martinez JP (1997) Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 54:56-60